What Else Can Semaglutide Treat? Uses Beyond Weight Loss

Semaglutide started as a type 2 diabetes drug. Then it became the most talked-about weight loss drug in the country. Since then it has picked up approvals for heart protection, kidney disease and liver disease, and it is being tested in dozens of other conditions, from alcohol cravings to knee pain.

This guide sorts the whole picture into three buckets: what semaglutide is actually approved to treat right now, what the research suggests but has not proven, and which big headlines turned out to be wrong. Nothing here is medical advice, and none of it tells you what to take. It is a map of the evidence so you can have a better conversation with your own healthcare provider.

What is semaglutide actually approved to treat right now?

Semaglutide is sold in the United States under three brand names, and each one has its own list of approved uses. This trips up a lot of people, so it is worth being precise.

Ozempic (semaglutide injection, 0.25 mg to 2 mg weekly) is approved [1]:

• to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise
• to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease
• to reduce the risk of sustained kidney function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

Wegovy (semaglutide injection up to 2.4 mg weekly, plus Wegovy tablets) is approved [2]:

• to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight
• to reduce excess body weight and keep it off long term in adults with obesity, adults with overweight plus at least one weight-related condition, and children aged 12 and older with obesity
• to treat noncirrhotic metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced liver fibrosis in adults

Rybelsus (oral semaglutide, 7 mg or 14 mg daily) is approved for type 2 diabetes and, since October 2025, to reduce major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk, whether or not they have already had a heart attack or stroke [3].

Two practical takeaways. First, Ozempic is not approved for weight loss, even though it contains the same drug as Wegovy. Second, the Wegovy injection and the Wegovy tablets do not have identical indication lists in the current label, so the pill and the shot are not interchangeable on paper.

Does semaglutide protect the kidneys?

Yes, and this is one of the strongest pieces of evidence outside of weight and blood sugar.

The FLOW trial randomized 3,533 adults who had both type 2 diabetes and chronic kidney disease to semaglutide 1 mg weekly or placebo, on top of their usual care [4]. It was stopped early because the benefit was clear. After a median of 3.4 years, the combined risk of kidney failure, a sustained 50 percent drop in kidney function, kidney death or cardiovascular death was 24 percent lower with semaglutide. Cardiovascular death alone was 29 percent lower, and kidney function declined more slowly.

The FDA added the kidney indication to the Ozempic label on January 28, 2025, making semaglutide the only GLP-1 drug with that approval [5].

One important limit: everyone in FLOW had type 2 diabetes. A smaller trial called SMART tested semaglutide 2.4 mg for 24 weeks in 101 people who had kidney disease and excess weight but no diabetes. It found reductions in protein in the urine, weight and blood pressure, but 24 weeks and a lab marker are not the same as a multi-year outcomes trial.

Can semaglutide treat fatty liver disease?

Yes, for a specific stage of it. In August 2025 the FDA granted accelerated approval to Wegovy 2.4 mg for adults with noncirrhotic MASH and moderate to advanced liver scarring, stages F2 to F3 [6]. MASH used to be called NASH, or nonalcoholic steatohepatitis.

The approval came from Part 1 of the ESSENCE trial. At week 72, 63 percent of people on semaglutide had their steatohepatitis resolve without their fibrosis getting worse, compared with 34 percent on placebo. Fibrosis improved without MASH worsening in 37 percent versus 22 percent [7].

Two caveats worth knowing. The approval is “accelerated,” which means it rests on liver biopsy findings rather than on proof that people live longer or avoid transplants. Novo Nordisk has to deliver that confirmatory evidence from the second part of the trial, expected around 2029. And the indication specifically excludes cirrhosis.

Does semaglutide help heart failure?

The research says yes for symptoms. The FDA label does not say so at all, which is a distinction worth understanding.

Two trials, STEP-HFpEF and STEP-HFpEF DM, tested semaglutide 2.4 mg in a total of about 1,145 adults with obesity-related heart failure with preserved ejection fraction, the type of heart failure where the heart pumps normally but does not fill well. Both found meaningfully better heart failure symptom scores, better physical function and more weight loss than placebo over a year [8].

But those endpoints were about how people felt and moved, not about hospitalizations or deaths. Novo Nordisk withdrew its US application in August 2024 after the FDA indicated it wanted more cardiovascular events to substantiate the effect, and said it would resubmit [9]. European regulators did update the Wegovy label. As of the current US prescribing information, heart failure is not on the American label [2].

If you see a headline saying “Wegovy approved for heart failure,” check which country it refers to.

Can semaglutide help with leg pain from poor circulation?

This is peripheral artery disease, where narrowed arteries in the legs cause cramping pain when you walk. The STRIDE trial was the first dedicated study of a GLP-1 drug for walking ability in this condition.

It randomized 792 adults with type 2 diabetes and symptomatic peripheral artery disease to semaglutide 1 mg or placebo for 52 weeks. Maximum treadmill walking distance improved 13 percent more with semaglutide, a median of about 26 meters further than placebo, with better quality-of-life scores as well [10].

European regulators adopted a positive opinion to add STRIDE data to the Ozempic label in June 2025. Novo Nordisk also filed with the FDA, but a peripheral artery disease indication does not appear in the current US Ozempic prescribing information [1].

Does semaglutide treat sleep apnea?

No, and this is the most common mix-up in the whole GLP-1 conversation.

The FDA approved a drug for moderate to severe obstructive sleep apnea in adults with obesity in December 2024. That drug is tirzepatide, sold as Zepbound, made by Eli Lilly. It is a different molecule that activates two hormone receptors instead of one [11]. In the SURMOUNT-OSA trials, tirzepatide reduced breathing interruptions by 25 to 29 events per hour compared with 5 to 6 on placebo.

Semaglutide has no sleep apnea indication. Despite being the most-prescribed GLP-1 drug in the world, it has never been tested in a randomized trial with sleep apnea severity as the primary outcome. Claims-based studies suggest people on anti-obesity medication develop sleep apnea less often, but that is not the same thing.

Can semaglutide slow Alzheimer’s disease?

No. This was the biggest disappointment in the field.

Novo Nordisk ran two of the largest Alzheimer’s trials ever conducted, EVOKE and EVOKE+, enrolling 3,808 people aged 55 to 85 with mild cognitive impairment or mild dementia and confirmed amyloid in the brain, across 40 countries. Participants took oral semaglutide 14 mg daily or placebo.

On November 24, 2025, the company announced the trials did not show a statistically significant reduction in disease progression [12]. At the CTAD conference the following month, the decline curves for the semaglutide and placebo groups were shown lying essentially on top of each other, on the primary measure and on every secondary cognitive and functional measure. The planned one-year extension was discontinued.

A few markers did move. In a small spinal fluid substudy, seven Alzheimer’s-related biomarkers dropped by 10 percent or less. A blood marker of inflammation, high-sensitivity C-reactive protein, fell about 30 percent. Neither translated into better thinking or function.

This matters because many observational studies had linked semaglutide to lower dementia rates in people with type 2 diabetes. It is a clean example of why those studies, however large, are not the same as a randomized trial.

Does semaglutide help knee arthritis?

The STEP 9 trial enrolled 407 adults with obesity and moderate knee osteoarthritis with at least moderately severe pain. Over 68 weeks, body weight fell 13.7 percent with semaglutide versus 3.2 percent with placebo, and the WOMAC pain score fell 41.7 points versus 27.5 points [13].

That is a real difference, but read the placebo column. People on placebo also improved a lot, so the extra benefit attributable to semaglutide was roughly 14 points on a 0 to 100 scale. The trial also did not test whether the drug changes the joint itself or delays knee replacement. There is no arthritis indication.

What about type 1 diabetes?

Semaglutide is not approved for type 1 diabetes, and using it there is investigational. But the first randomized evidence arrived in 2025.

ADJUST-T1D randomized 72 adults who had type 1 diabetes and obesity and were already using an automated insulin delivery system to semaglutide up to 1 mg or placebo for 26 weeks. A composite target combining good time in range, low hypoglycemia and at least 5 percent weight loss was reached by 36 percent of the semaglutide group and none of the placebo group [14]. Average weight loss was about 18.5 pounds, without more severe low blood sugar or diabetic ketoacidosis.

Seventy-two people over six months is a starting point, not a conclusion. Everyone was on an automated pump, so the findings do not transfer cleanly to people using injections.

Does semaglutide lower or raise cancer risk?

Both claims circulate, and the honest answer is that the evidence points in different directions depending on the study design.

On the reassuring side, a 2026 analysis in Annals of Oncology matched 80,899 adults with obesity and no diabetes who took a GLP-1 drug against 80,899 who received diet or exercise counseling. Over a median two years, the GLP-1 group had a 41 percent lower rate of 13 obesity-associated cancers (HR 0.59), with the largest reductions in men and a 58 percent lower rate of endometrial cancer [15].

Two caveats matter for anyone reading that number as a semaglutide number. It is a whole-class figure, and the authors reported that the largest reduction came from tirzepatide users; semaglutide’s own result was a smaller 20 percent reduction in cumulative cancer incidence (HR 0.80, 95 percent CI 0.68 to 0.94) [15]. And the benefit was not seen in Black patients, which the authors attributed to possible differences in access to care and risk profiles rather than to biology alone.

On the cautious side, a meta-analysis of randomized trials found no overall cancer increase but flagged possible signals for thyroid cancer and colorectal cancer [16]. Other large analyses have found no difference across a dozen cancer types. And every semaglutide product carries a boxed warning based on thyroid C-cell tumors in rodents, with a contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 [2].

Cancer takes years to develop, and most of these studies follow people for about two. Treat both the good news and the bad news as preliminary.

What else is being studied?

A partial list of areas with published human data as of September 2026:

• Alcohol use disorder. Three randomized trials have now reported, including a 2026 Lancet trial in 108 people that cut heavy drinking days substantially. No approval exists.
• Smoking. A 2026 phase 2a trial missed its main endpoint but reduced cigarette craving.
• Polycystic ovary syndrome. Small trials show weight, metabolic and menstrual improvements, mostly in women who also have obesity.
• Psoriasis and hidradenitis suppurativa. Small open-label trials and cohorts show skin disease scores improving, with inflammatory markers falling too.
• Asthma and COPD. A real-world analysis of UK electronic health records, presented at the European Respiratory Society congress in September 2026, linked semaglutide to about 38 to 40 percent fewer asthma attacks and about 20 percent fewer COPD flare-ups compared with sulfonylureas, a specific older diabetes drug class rather than diabetes treatment in general. The investigators explicitly said nobody should start a GLP-1 drug for a lung condition on that basis, and the work is a conference presentation, not a peer-reviewed paper [17].
• Weight regain after bariatric surgery. The BARI-STEP trial randomized 70 people whose surgery had produced less than 20 percent weight loss. Those on semaglutide lost 18.0 percent of body weight over 68 weeks; the placebo group gained 0.4 percent [18].
• Obesity in children aged 6 to 11. Novo Nordisk reported in September 2026 that 40.4 percent of children in the STEP Young trial were no longer classified as having obesity after 68 weeks, versus none on placebo [19]. No GLP-1 drug is approved under age 12.

What happens if you stop taking it?

Most of the weight comes back. In the STEP 1 trial extension, people who stopped semaglutide regained 11.6 percentage points of their lost weight by week 120, compared with 1.9 points in the placebo group, leaving net losses of 5.6 percent and 0.1 percent [20]. A 2026 systematic review found regain follows a predictable, slowing curve that levels off somewhat below starting weight.

This is why clinicians increasingly describe these drugs the way they describe blood pressure medication: something you stay on if it is working and you can tolerate it, not a short course.

The bottom line

Semaglutide’s approved list has grown from one condition to several in under a decade, and the strongest additions, kidney disease and liver disease, came from large trials with hard endpoints. The investigational list is much longer and much shakier, and at least two headline hypotheses, Alzheimer’s disease and heart failure event reduction, have not delivered what people hoped.

If you are taking semaglutide or considering it, the useful questions for your healthcare provider are which brand and indication apply to your situation, what your insurance covers for that specific indication, and what the plan is if you need to stop. No article can answer those for you.

Sources

1. Ozempic (semaglutide) injection US prescribing information — Novo Nordisk
2. Wegovy (semaglutide) injection and tablets US prescribing information — Novo Nordisk
3. FDA approves Novo Nordisk’s oral semaglutide for cardiovascular risk reduction — Novo Nordisk via PR Newswire, October 17, 2025
4. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) — New England Journal of Medicine, 2024
5. FDA approves Ozempic to reduce the risk of worsening kidney disease and cardiovascular death — Novo Nordisk via PR Newswire, January 28, 2025
6. FDA Approves Treatment for Serious Liver Disease Known as ‘MASH’ — US Food and Drug Administration, August 15, 2025
7. Wegovy approved by FDA for adults with noncirrhotic MASH with moderate to advanced liver fibrosis — Novo Nordisk via PR Newswire, August 15, 2025
8. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity — New England Journal of Medicine, 2023
9. Novo Nordisk pulls its FDA heart failure submission for Wegovy — Fierce Pharma, August 2024
10. Semaglutide and Walking Capacity in People With Symptomatic PAD and Type 2 Diabetes (STRIDE) — American College of Cardiology, March 2025
11. FDA Approves First Medication for Obstructive Sleep Apnea — US Food and Drug Administration, December 2024
12. Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer’s disease progression — Novo Nordisk, November 24, 2025
13. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (STEP 9) — New England Journal of Medicine, 2024
14. Semaglutide in Adults with Type 1 Diabetes and Obesity (ADJUST-T1D) — NEJM Evidence, 2025
15. GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults — Annals of Oncology, June 2026
16. GLP-1 receptor agonists and the risk for cancer: a meta-analysis — Diabetes, Obesity and Metabolism, May 2025
17. Weight loss injection semaglutide can reduce asthma attacks by up to 40 per cent — European Respiratory Society, September 8, 2026
18. Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery (BARI-STEP) — Nature Medicine, May 2026
19. STEP Young phase 3 data — Novo Nordisk, September 7, 2026
20. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension — Diabetes, Obesity and Metabolism, 2022